Is this the BEST weight loss peptide?
About this video
Gillett and O’Hara react to fresh trial results for a combination product pairing semaglutide with an amylin analog, which they say slightly trailed tirzepatide on weight loss despite strong absolute results. They argue the headline weight number misses potentially important outcomes — body composition, muscle preservation, glycemic control, and tolerability — that they wish trials reported routinely. Gillett offers the hot take that few non-diabetic people should use maximum GLP-1 doses, favoring lower doses paired with lifestyle change, and predicts amylin-based combinations will prove especially valuable for insulin-dependent diabetics. They also criticize influencer marketing of unapproved triple-agonist peptides, noting nobody can verify what those products actually contain.
Key takeaways
- The hosts argue weight loss alone is an incomplete scorecard; body composition and metabolic markers matter
- They claim most non-diabetic users would do better on below-maximum doses plus lifestyle change
- Amylin biology is presented as an underappreciated piece of diabetes progression and a promising drug target
- They predict combining an amylin analog with a dual incretin could outperform current options on tolerability
- Unapproved peptides sold through influencer codes are flagged as unverifiable and risky
Episode details: published February 24, 2026 · 613 views · 10:01 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.
← Previous: Sarms, False Advertising, & The HCG Diet | @proteinbrospodcast · Next: Do peptides actually work? Experts Explain →
All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)
